SOURCE: StockCall

StockCall

May 13, 2011 09:03 ET

Opinions on Amgen Inc. and Biogen Idec Inc. -- Acquisition and R&D Trends in Biotech

JOHANNESBURG, SOUTH AFRICA--(Marketwire - May 13, 2011) - www.stockcall.com/ offers investors comprehensive research on the Biotechnology industry and has completed analytical research on Amgen Inc. (NASDAQ: AMGN) and Biogen Idec Inc. (NASDAQ: BIIB). Register with us today at www.stockcall.com/ to have free access to these researches.

The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Larger firms are leaning on acquisitions to quickly expand their product lines while smaller ones are opting for increased spending on research and development. Regardless of the approach, success in the increasingly competitive industry hinges on maintaining a pipeline, especially with so many drugs facing expiring exclusivity rights this year. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Biotechnology industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the Biotechnology industry can have easy and free access to our analyst research and opinions on Amgen Inc. and Biogen Idec Inc.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

Amgen Inc. is among the companies upping their spending on R&D. In their most recent quarter, they reported a 14% increase on research and development costs. They also projected R&D costs to be about 18-20% of total revenues in 2011. Investors looking for free research on Amgen Inc. are welcome to sign up at www.stockcall.com/AMGN130511.pdf.

Similarly, Biogen Idec Inc. reported R&D expenses of $292 million or 24% of revenues for the first quarter. Investors looking for free research on Biogen Idec Inc. are welcome to sign up at www.stockcall.com/BIIB130511.pdf.

Moving forward, big pharma may continue to focus on acquisitions for the remainder of the year, while smaller biotech companies look to increasing R&D spending to get new products to market. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information